



## Neutralizing Antibodies against SARS-CoV-2 and HIV

Guest Editor:

### Dr. Zhi Yang

Department of Cell and  
Molecular Biology, University of  
California, Berkeley, CA, USA

Deadline for manuscript  
submissions:

**closed (1 August 2024)**

### Message from the Guest Editor

This Special Issue of *Vaccines* includes a collection of reviews and research articles that focus on neutralizing antibodies (NAbs) against SARS-CoV-2 and HIV viruses, covering topics such as the cellular and molecular mechanisms of antibody-mediated antiviral activities, analyses of the antibodies' epitopes on viral antigens, structural bases of the antibody–antigen interactions, as well as implications of therapeutic developments. Our Special Issue aims to provide opinions/commentaries, summaries, and in-depth analyses of neutralizing antibodies against SARS-CoV-2 and HIV-1. In this Special Issue, research areas may include but are not limited to:

- Molecular mechanisms of antigen–antibody interactions of neutralizing, as well as certain non-neutralizing, antibodies against SARS-CoV-2 or HIV-1;
- Analyses of antibody epitopes on SARS-CoV-2 S or HIV-1 Env antigens;
- Current progress and limitations of antibody-based therapeutic development;
- Current progress and limitations of Nabs structure-based immunogen design;
- Your proposed topics that you believe would be potentially interesting to our community.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)